Program - Society of Toxicology

44 th Annual Meeting
and ToxExpo
Program Description
#1972 9:55 CROSS-SPECIES COMPARISONS OF
TRANSCRIPTIONAL RESPONSES IN PRIMARY
HEPATOCYTES. W. B. Mattes, K. Daniels, D. L.
Mendrick and M. S. Orr. Toxicogenomics, Gene Logic
Inc., Gaithersburg, MD.
#1973 10:20 TOXICO- AND PHARMACOGENETIC ANALYSIS
IN A NOVEL MODEL OF PARKINSON’S
DISEASE: DOPAMINE NEURON
DEGENERATION IN C. ELEGANS. R. Nass, C.
Nichols, M. Fullard, M. Garrett and M. Marvanova.
Anesthesiology and Pharmacology, and Center for
Molecular Neuroscience, Vanderbilt University Medical
Center, Nashville, TN. Sponsor: B. Mattes.
Thursday Morning, March 10
8:30 AM to 11:30 AM
Room 208
SYMPOSIUM SESSION: DEVELOPMENTAL EXPRESSION OF
HUMAN PHASE I AND PHASE II TOXICANT METABOLIZING
ENZYMES: IMPACT ON EARLY LIFE STAGE SUSCEPTIBILITY
Chairperson(s): Ronald Hines, Medical College of Wisconsin, Milwaukee, WI
and Melissa A. Runge-Morris, Wayne State University, Detroit, MI.
Endorsed by:
Mechanisms SS
Risk Assessment SS
Student Advisory Committee
Over the past several years, there has been considerable interest in the dynamic
changes that occur in toxicokinetic factors during early life stages and how these
changes may impact differential toxicant susceptibility. Advances in molecular
and analytical techniques have allowed a better characterization of these
changes, as well as some of the underlying control mechanisms. The objectives
of this symposium are to: 1) present examples of the information gained about
major members of the oxidative Phase I enzymes and how this information has
led to the identification of common developmental themes; 2) present information
on the developmental expression of two conjugative phase II enzyme
classes, N-acetyl transferases and sulfotransferases, and how, combined with the
information regarding phase I enzymes, can inform regarding possible differential
susceptibility during ontogeny; and 3) demonstrate how such information
regarding developmental expression can be integrated into physiological-based
toxicokinetic models for predicting temporal-specific changes in toxicant disposition
useful for early life stage risk assessment. These advances offer the
promise and challenge of predicting changing dose-response relationships
during early life and the possible prevention of developmental toxicity.
#1974 8:30 ONTOGENY OF HUMAN HEPATIC PHASE I
AND PHASE II ENZYMES: IMPLICATIONS FOR
DIFFERENTIAL TOXICANT SUSCEPTIBILITY.
R. N. Hines 1 and M. A. Runge-Morris 2 . 1 Pediatrics,
Medical College of Wisconsin, Milwaukee, WI and
2 Inst. Env. Hlth. Sciences., Wayne State University,
Detroit, MI.
#1975 8:35 HUMAN HEPATIC PHASE I ENZYME
DEVELOPMENTAL EXPRESSION. R. N. Hines.
Pediatrics, Med. Col. Wisconsin, Milwaukee, WI.
#1976 9:15 SULFOTRANSFERASE EXPRESSION:
IMPLICATIONS FOR PRENATAL TOXICITY. M.
Runge-Morris. Inst. Envir. Health Sciences., Wayne
State University, Detroit, MI.
#1977 9:55 DEVELOPMENTAL EXPRESSION OF HUMAN
AND MURINE ARYLAMINE N-
ACETYLTRANSFERASES(NAT):
IMPLICATIONS FOR AROMATIC AMINE
GENOTOXICITY. C. A. McQueen. University of
Arizona, Tucson, AZ.
#1978 10:35 DEVELOPMENT OF PHYSIOLOGICALLY-
BASED TOXICOKINETIC MODELS FOR EARLY
LIFE STAGES: IMPLICATIONS FOR
DIFFERENTIAL TOXICANT SUSCEPTIBILITY.
D. Hattis 1 , G. Ginsberg 2 , B. Sonawane 3 and K. Walker 4 .
1 2 Clark University, Worcester, MA, CT Department of
Public Health, Hartford, CT, 3 U.S. EPA, Washington,
DC and 4 Clark University, Worcester, MA.
Thursday Morning, March 10
8:30 AM to 11:30 AM
Room 220
SYMPOSIUM SESSION: SYSTEMS BIOLOGY: APPROACHES AND
APPLICATIONS TO TOXICOLOGY
Chairperson(s): William Slikker, Jr., National Center for Toxicological
Research, Jefferson, AR and Thomas Knudsen, University of Louisville, School
of Dentistry, Louisville, KY.
Endorsed by:
Neurotoxicology SS
Reproductive and Development SS
Risk Assessment SS*
Genomics and proteomics provide information on the cellular reaction to drug
and chemical exposures but this is only part of what is needed to understand
complex developing systems, where susceptibilities to exposure may advance
through transitional states of varying susceptibilities. The NIH Director’s Road
Map has focused on the need to provide new tools to investigators, to speed the
process of discovery, to encourage interdisciplinary research, and to promote
translational research. Systems biology will contribute to this missive. Systems
biology is the application of systems theory to solving biological problems and
is a means to analyze complex behavior in a composite system that may be
decomposed into subsystems to facilitate understanding and modeling. In toxicology,
it provides a means for identifying pathways that are critical to disease
and to discovering on- and off- target effects of compounds. Devising computational
models and integrating these models with empirical data provide
important insight into complex systems-level behaviors, ultimately striving to
deliver the mechanism connecting small molecules (drug or chemical) with a
clinical endpoint (phenotype or disease) with regards to metabolic and regulatory
networks. The integrative topic of systems biology and application
examples focused on several organ systems and stages of development will
interests toxicologists with backgrounds in mechanisms, reproduction, development,
neuroscience, modeling, and safety and risk assessment.
#1979 8:30 SYSTEMS BIOLOGY: APPROACHES AND
APPLICATIONS TO TOXICOLOGY. W. Slikker 1
and T. B. Knudsen 2 . 1 Division of Neurotoxicology,
NCTR/FDA, Jefferson, AR and 2 Department of
Molecular, Cellular and Craniofacial Biology Birth
Defects Center, University of Lousiville, School of
Dentistry, Louisville, KY.
#1980 9:00 EXTRACTING MEANING FROM EXPRESSION
DATA. J. Quackenbush. Institute for Genomic
Research, Rockville, MD. Sponsor: T. Knudsen.
THURSDAY
up-to-date information at www.toxicology.org 201